A phase II clinical trial to analyze olaparib response in patients with BRCA1 and/or BRCA 2 promoter methylation with advanced breast cancer (GEICAM/2015-06 COMETA-Breast study).

Juan De La Haba; Angel Guerrero-Zotano; Jose Alejandro Perez-Fidalgo; Santiago Gonzalez Santiago; Montserrat Muñoz; Raquel Andres; Cristina Cruz Zambrano; Sebastian Moran Salama; Sara Lopez-Tarruella; Vanesa Quiroga Garcia; Sonia Servitja; Mireia Mele; Sonia Alonso Soler; Barbara Adamo; Maria Jose Escudero; Nuria Martin; Susana Bezares; Rosalia Caballero; Manel Esteller; Federico Rojo

Journal Article

A phase II clinical trial to analyze olaparib response in patients with BRCA1 and/or BRCA 2 promoter methylation with advanced breast cancer (GEICAM/2015-06 COMETA-Breast study).

De La Haba J
Guerrero-Zotano A
Perez-Fidalgo J
et al.

Journal of Clinical Oncology (2018) 36(15_suppl) TPS1114-TPS1114

DOI: 10.1200/jco.2018.36.15_suppl.tps1114

N/ACitations

5Readers

Get full text

Abstract

TPS1114Background: Identification of targeted therapies for advanced triple negative breast cancer (TNBC) remains as an important clinical challenge. TNBC frequently shows BRCA dysfunction and 80% ...

Cite

CITATION STYLE

APA

De La Haba, J., Guerrero-Zotano, A., Perez-Fidalgo, J. A., Gonzalez Santiago, S., Muñoz, M., Andres, R., … Rojo, F. (2018). A phase II clinical trial to analyze olaparib response in patients with BRCA1 and/or BRCA 2 promoter methylation with advanced breast cancer (GEICAM/2015-06 COMETA-Breast study). Journal of Clinical Oncology, 36(15_suppl), TPS1114–TPS1114. https://doi.org/10.1200/jco.2018.36.15_suppl.tps1114

A phase II clinical trial to analyze olaparib response in patients with BRCA1 and/or BRCA 2 promoter methylation with advanced breast cancer (GEICAM/2015-06 COMETA-Breast study).

Abstract

Cite

Register to see more suggestions